【摘要】 探讨多药耐药基因(MDR1)和多药耐药相关蛋白基因(MRP)在非小细胞肺癌(NSCLC)中的表达、意义及相关关系。方法:采用原位分子杂交对113例NSCLC组织中MDR1和MRP基因mRNA的表达进行检测。结果:MDR1和MRP基因mRNA在NSCLC组织中的阳性表达率分别为51.3%(58/113)、80.5%(91/113),二者与NSCLC肿瘤组织类型、分化程度、淋巴结转移、TNM分期等无关(P>0.05)。MDR1和MRP的协同阳性(MDR1+/MRP+)表达率为48.7%(55/113),二者在NSCLC中的表达之间存在明显相关(P<0.01)。结论:MDR1和MRP是NSCLC原发性多药耐药的重要参与因素,二者联合检测对临床NSCLC的化疗具有指导意义。更多还原

【Abstract】 Objective: To evaluate expression of multidrug resistance gene (MDR1) and multidrug-resistance related protein (MRP) gene in non-small cell lung cancer and their involvment in multidrug-resistance. Methods: Expression of MDR1 and MRP gene mRNA in paraffin-embedded cancer tissues from 113 non-small cell lung cancer patients was determined by in situ hybridization. Results: The positive expression of MDR1 and MRP were observed in 58 (51.3%) cases and 91 (80.5%) cases of non-small cell lung cancer respectively. The expression of MDR1 and MRP was not related to histological subtypes, cell differentiation, TNM staging and lymphatic metastasis (P>0.05). The positive expression of both MDR1 and MRP was observed in 55 (48.8%) cases. And there is a significant correlation between expression of MDR1 and MRP in NSCLC (P<0.01). Conclusions: Both of MDR1 and MRP play significant roles in intrinsic multidrug resistance of non-small cell lung cancer. It is important to detect MDR1 and MRP gene expression in directing chemotherapy of lung carcinoma.更多还原